Relmada and NeurAxis Q4 2025: Clinical Milestones and Commercial Scaling
Key Takeaways
- Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting critical pivots in clinical development and commercial execution.
- Relmada remains focused on its Phase 3 REL-1017 program for depression, while NeurAxis reports steady growth in its neuromodulation therapy for pediatric patients.
Mentioned
Key Intelligence
Key Facts
- 1Relmada is focused on the Phase 3 RELIANCE II and RELIANCE III trials for REL-1017 in Major Depressive Disorder.
- 2NeurAxis reported continued commercial expansion of its IB-Stim device for pediatric functional abdominal pain.
- 3Relmada's management emphasized trial protocol refinements to mitigate placebo response in psychiatric studies.
- 4NeurAxis is prioritizing the expansion of insurance coverage and Medicaid reimbursement to drive revenue growth.
- 5Both companies reported Q4 2025 results in March 2026, reflecting a period of high R&D and commercial investment.
| Metric/Feature | ||
|---|---|---|
| Core Product | REL-1017 (Drug) | IB-Stim (Device) |
| Primary Indication | Major Depressive Disorder | Pediatric Abdominal Pain |
| Development Stage | Late-Stage Clinical (Phase 3) | Commercial-Stage |
| Key Catalyst 2026 | Phase 3 Data Readout | Insurance Coverage Expansion |
| Primary Risk | Clinical Trial Failure | Commercial Execution/Reimbursement |
Analysis
The fourth-quarter 2025 earnings reports for Relmada Therapeutics and NeurAxis highlight a significant divergence in the small-cap healthcare sector, illustrating the distinct challenges faced by clinical-stage drug developers versus commercial-stage medical technology firms. As the market entered 2026, both companies demonstrated a sharpened focus on their respective paths to value creation: Relmada through the high-stakes clinical validation of its lead antidepressant candidate, and NeurAxis through the expansion of insurance coverage and market penetration for its pediatric neuromodulation device.
Relmada Therapeutics, led by CEO Sergio Traversa, remains centered on the development of REL-1017 (esmethadone), a novel NMDA receptor antagonist for the treatment of Major Depressive Disorder (MDD). During the Q4 call, management emphasized the progress of the RELIANCE II (Study 302) and RELIANCE III (Study 303) trials. These studies are critical for Relmada, as they aim to provide the definitive data required for a New Drug Application (NDA) submission. The company's strategy has been to refine its trial protocols to minimize the placebo effect, a perennial challenge in psychiatric drug development. CFO Raj Pruthi noted that the company’s financial position remains a primary focus, with R&D expenses reflecting the intensive nature of these late-stage trials. For investors, the timeline for the RELIANCE II readout is the most significant upcoming catalyst, as it will determine whether REL-1017 can successfully differentiate itself in a crowded MDD market currently dominated by generic SSRIs and newer, faster-acting treatments like Spravato.
Relmada Therapeutics, led by CEO Sergio Traversa, remains centered on the development of REL-1017 (esmethadone), a novel NMDA receptor antagonist for the treatment of Major Depressive Disorder (MDD).
In contrast, NeurAxis is navigating the 'commercial chasm'—the difficult transition from FDA clearance to widespread clinical adoption and reimbursement. The company’s IB-Stim device, which uses percutaneous electrical nerve field stimulation (PENFS) to treat functional abdominal pain associated with IBS in adolescents, has seen steady growth. The Q4 results underscored the importance of securing favorable coverage policies from major private insurers and state Medicaid programs. For a medtech company like NeurAxis, the metric of success is no longer just clinical efficacy, but the 'reimbursement footprint.' Management highlighted that as more payers recognize the cost-effectiveness of non-pharmacological interventions for pediatric pain, the total addressable market for IB-Stim expands significantly. This commercial scaling is essential for NeurAxis to achieve cash-flow positivity, a milestone that remains a top priority for its leadership team.
What to Watch
The broader market context for these two companies is defined by a cautious but recovering sentiment toward small-cap healthcare. After a period of high interest rates that pressured valuations for pre-revenue and early-commercial companies, the stabilization of the macroeconomic environment in late 2025 provided a more supportive backdrop. However, the 'show-me' story remains dominant. For Relmada, this means delivering clean, statistically significant Phase 3 data. For NeurAxis, it means demonstrating a clear trajectory toward profitability through consistent revenue growth and margin expansion. The divergence in their business models—Relmada’s binary clinical outcomes versus NeurAxis’s incremental commercial gains—offers investors two different ways to play the healthcare innovation space.
Looking ahead into 2026, the primary risks for Relmada include potential trial delays or data that fails to meet the primary endpoint, which would be catastrophic for its valuation. For NeurAxis, the risks are more operational, centered on sales force execution and the speed of payer negotiations. Both companies are at an inflection point where their 2025 performance has set the stage for what could be a transformative year. Analysts will be watching closely for any updates on Relmada’s enrollment rates and NeurAxis’s quarterly revenue per unit, as these will be the leading indicators of long-term success in their respective niches.
From the Network
Relmada Therapeutics Advances REL-1017 Trials Amid Q4 2025 Financial Review
Relmada Therapeutics reported its Q4 2025 results, highlighting progress in its Phase 3 REL-1017 program for major depressive disorder. The company remains focused on completing enrollment for its piv
HealthcareRelmada and NeurAxis Q4 Results Signal Pivotal 2026 for CNS Innovation
Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting a strategic shift toward late-stage clinical readouts and expanded commercial coverage for CNS therapies. Both companies are po
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |